Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
16,724,051
-
Total 13F shares
-
928,766
-
Share change
-
+293,293
-
Total reported value
-
$1,477,067
-
Put/Call ratio
-
90%
-
Price per share
-
$1.59
-
Number of holders
-
31
-
Value change
-
+$473,601
-
Number of buys
-
14
-
Number of sells
-
10
Institutional Holders of Citius Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (CTXR) as of Q2 2025
As of 30 Jun 2025,
Citius Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (CTXR) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
928,766 shares.
The largest 10 holders included
UBS Group AG, Cambridge Investment Research Advisors, Inc., HEIGHTS CAPITAL MANAGEMENT, INC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc., NewEdge Advisors, LLC, STATE STREET CORP, XTX Topco Ltd, and Arkadios Wealth Advisors.
This page lists
31
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.